在局部晚期切除的食道状细胞癌中使用新辅助剂阿德布雷利马布:一期1b试验
Jun Yin1, Jingnan Yuan2,3,4, Yunjin Li2,4
1Department of Thoracic Surgery, Cancer Center, Zhongshan Hospital of Fudan University, Shanghai, China.
使用阿德布雷利马布的新辅助免疫疗法对可切除食道状细胞癌具有前景,证明了安全性和可行性. 这种方法可以通过调节瘤微环境来改善结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道癌症 胃肠道癌症
背景情况:
- 新辅助免疫疗法对局部晚期食道状细胞癌 (ESCC) 的益处尚未得到充分证实.
- 确定治疗反应的预测生物标志物至关重要.
研究的目的:
- 评估新辅助剂PD-L1阻断与adbrelimab在可切除ESCC中的安全性,可行性和有效性.
- 探索与治疗反应相关的瘤微环境特征.
主要方法:
- 一个1b期试验,涉及可切除ESCC的患者,在手术前接受两剂新辅助剂阿德布雷利马布.
- 评估安全性,可行性,病理完整反应 (pCR),整体存活率 (OS) 和瘤微环境表型.
主要成果:
- 该试验符合安全性和可行性的主要终点,并具有可管理的不良事件 (厌食症,疲劳).
- 24%的患者实现了重大病理反应,包括8%的PCR率. 两年后的正常运行率为92%.
- 响应患者表现出免疫丰富的瘤微环境和特定的内T细胞动态,与不响应患者不同.
结论:
- 新辅助剂阿德布雷利马布对可切除ESCC是安全和可行的,显示了令人鼓舞的响应率和生存数据.
- 瘤微环境特征,包括免疫细胞透和T细胞克隆性,可以预测对抗PD-L1疗法的反应.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Barrett Esophagus-I: Introduction
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
Treatment Resistant Cancers
